Loading...
Market
Will gene therapy for sickle cell disease receive FDA approval for commercial use by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
12-Year-Old Kendric Cromer First to Receive Approved Gene Therapy for Sickle Cell Disease
Oct 22, 2024, 12:38 AM
Gene therapy has shown promising results in treating sickle cell disease, with a significant milestone achieved recently. Kendric Cromer, a 12-year-old boy, became the first patient to receive an approved gene therapy for sickle cell disease. After spending 44 days in the hospital, he was discharged from Children’s National Hospital in Washington. Kendric expressed his relief, saying, “I thought I would have sickle cell for the rest of my life.” The therapy offers hope to the approximately 100,000 people in the U.S. who have sickle cell disease, particularly the 20,000 with the most severe cases. However, the treatment comes with challenges and costs.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other major markets • 25%
Not approved in any major market • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Universal gene therapy • 33%
Mutation-specific gene therapy • 33%
No approval • 34%
Yes • 50%
No • 50%
